CA2419405A1 - Steroid hormones as transfer agents - Google Patents

Steroid hormones as transfer agents Download PDF

Info

Publication number
CA2419405A1
CA2419405A1 CA002419405A CA2419405A CA2419405A1 CA 2419405 A1 CA2419405 A1 CA 2419405A1 CA 002419405 A CA002419405 A CA 002419405A CA 2419405 A CA2419405 A CA 2419405A CA 2419405 A1 CA2419405 A1 CA 2419405A1
Authority
CA
Canada
Prior art keywords
steroid hormone
pharmaceutically active
active compound
hormone
progesterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002419405A
Other languages
English (en)
French (fr)
Inventor
Charlotte Hauser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Octagene GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octagene GmbH filed Critical Octagene GmbH
Publication of CA2419405A1 publication Critical patent/CA2419405A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002419405A 2000-08-15 2001-08-15 Steroid hormones as transfer agents Abandoned CA2419405A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00202858A EP1180364A1 (de) 2000-08-15 2000-08-15 Steroidhormone als Übertragungsmittel
EP00202858.7 2000-08-15
PCT/EP2001/009409 WO2002013791A2 (en) 2000-08-15 2001-08-15 Steroid hormones as transfer agents

Publications (1)

Publication Number Publication Date
CA2419405A1 true CA2419405A1 (en) 2002-02-21

Family

ID=8171921

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002419405A Abandoned CA2419405A1 (en) 2000-08-15 2001-08-15 Steroid hormones as transfer agents

Country Status (11)

Country Link
US (1) US20040028740A1 (de)
EP (2) EP1180364A1 (de)
JP (1) JP2004506006A (de)
AU (1) AU2001291766A1 (de)
CA (1) CA2419405A1 (de)
CZ (1) CZ2003450A3 (de)
HU (1) HUP0300753A2 (de)
NZ (1) NZ524203A (de)
PL (1) PL366042A1 (de)
WO (1) WO2002013791A2 (de)
ZA (1) ZA200301237B (de)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB951767A (en) * 1959-03-25 1964-03-11 Upjohn Co Improvements in or relating to pharmaceutical compositions and the preparation thereof
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
GB1535531A (en) * 1976-10-15 1978-12-13 Warmer & Co Ltd W Pharmaceutical compositions
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
US5574022A (en) * 1994-04-14 1996-11-12 The Center For Innovative Technology Method of attenuating physical damage to the spinal cord
US5599822A (en) * 1995-06-06 1997-02-04 Eli Lilly And Company Methods for minimizing bone loss
WO1998042185A1 (en) * 1997-03-26 1998-10-01 Reprogen, Inc. Endometriosis mouse model
JP2002537311A (ja) * 1999-02-19 2002-11-05 オクタジーン・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ホルモン−ホルモン受容体の複合体および核酸構築物、並びに遺伝子治療におけるそれらの使用

Also Published As

Publication number Publication date
EP1311244A2 (de) 2003-05-21
NZ524203A (en) 2004-12-24
JP2004506006A (ja) 2004-02-26
HUP0300753A2 (hu) 2003-09-29
ZA200301237B (en) 2004-02-16
WO2002013791A2 (en) 2002-02-21
PL366042A1 (en) 2005-01-24
WO2002013791A3 (en) 2003-02-13
CZ2003450A3 (cs) 2003-09-17
US20040028740A1 (en) 2004-02-12
EP1180364A1 (de) 2002-02-20
AU2001291766A1 (en) 2002-02-25

Similar Documents

Publication Publication Date Title
JP6126072B2 (ja) 遺伝子発現を抑制する治療におけるリポソームによる効率的な送達のプロセスおよび組成物
KR101150242B1 (ko) 부신피질 자극 호르몬 유사체 및 관련 방법
Cohen et al. Colony-stimulating factor-1 plays a major role in the development of reproductive function in male mice
US20070004693A1 (en) Estrogen compositions for vaginal administration
WO1999040113A2 (fr) Lipopeptides contenant un fragment de l'interferon et leur utilisation dans des compositions pharmaceutiques
CZ20023585A3 (cs) Léčba rakoviny
TW590775B (en) Pharmaceutical compositions for increasing or decreasing phagocytosis in mammalian cells
Jung-Testas et al. Two sex steroid receptors in mouse fibroblasts in culture
JP2765822B2 (ja) 酸化防止作用を有するステロイドを含有する、ヒトにおける薬物ホルモン代用のための製薬学的調剤
US20040028740A1 (en) Steroid hormones as transfer agents
Crettaz et al. Transcriptional and posttranscriptional regulation of tyrosine aminotransferase by insulin in rat hepatoma cells
LT4441B (lt) Antigliukokortikoidinis vaistinis preparatas
Huang et al. Liposome and immunoliposome mediated delivery of proteins and peptides
KR20210113294A (ko) 16α-브로모-3β-히드록시-5α-안드로스탄-17-케톤 및 이의 수화물, 유도체 및 유사체를 포함하는 수성 현탁액 조성물, 제제 및 수분산 건조 조성물
JPWO2005054486A1 (ja) 遺伝子導入試薬調製法
WO2008049620A1 (en) Semi-solid controlled release composition
KR100940054B1 (ko) 호르몬 효과를 갖는 17알파-히드록시-14베타-스테로이드
Huang et al. Liposome and Immunoliposome Mediated Delivery of Proteins and Peptides
CA2093665A1 (en) Phospholipid analogue vesicle
Gibori Steroidal Regulation of Sterol Carrier Protein-2 and P450scc Expression in the Corpus Luteum
JPH09176183A (ja) 3α−ヒドロキシ−5α−アンドロスタ−16−エンの薬剤としての用途

Legal Events

Date Code Title Description
FZDE Discontinued